BBIO: Attruby's clinical edge and pipeline launches drive growth, with break-even targeted by 2027
The conference highlighted strong first-line growth and clinical differentiation for Attruby, robust pipeline progress with infigratinib and BBP-418, and a solid financial position targeting break-even by 2027. AI and China partnerships are enhancing operations, while pricing strategy relies on pro…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.